BMY vs MBX · P/E 17, rev $24.46B vs $1.98B cap
Bristol-Myers Squibb Company (BMY) versus MBX Biosciences, Inc. Common Stock (MBX) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
MBX Biosciences, Inc. Common Stock (MBX) is a biotechnology company listed on NASDAQ.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
MBX does not have a complete income-statement cache yet.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. MBX currently screens at market cap $1.98B.
Not investment advice. Open the BMY and MBX stock pages for the full models.
Not investment advice.